Several downstream effectors of the NF-κB pathway has been reported to have a role in BC incidence and progression, such as MDR-1 (32), c-Myc (33), Cox-2 (34), BCRP/ABCG2 (35) and VEGF, which are involved in regulating the response to chemotherapy, cellular growth, proliferation, and transmigration, respectively. Here, NFKB1 is linked to breast cancer.